Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Equity Ratio (2019 - 2025)

Goldenwell Biotech's Equity Ratio history spans 7 years, with the latest figure at 0.43 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 501.24% year-over-year to 0.43; the TTM value through Sep 2025 reached 0.43, down 501.24%, while the annual FY2024 figure was 0.21, 156.73% down from the prior year.
  • Equity Ratio reached 0.43 in Q3 2025 per GWLL's latest filing, down from 0.35 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q3 2022 to a low of 0.43 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.41, with a median of 0.65 recorded in 2021.
  • Peak YoY movement for Equity Ratio: soared 30.61% in 2022, then tumbled 1909.98% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.65 in 2021, then grew by 24.01% to 0.81 in 2022, then plummeted by 54.24% to 0.37 in 2023, then plummeted by 156.73% to 0.21 in 2024, then tumbled by 104.17% to 0.43 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Equity Ratio are 0.43 (Q3 2025), 0.35 (Q2 2025), and 0.43 (Q1 2025).